Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion

Table 2 Analysis predictors of progression-free survival and overall survival in patients with HCC

Variable	Univariate analysis			Multivariate analysis
Variable	HR	95% CI	p value	HR	95% CI	p value
Progression-free survival
Sex (male vs female)	1.27	0.73–2.37	0.507
Age, y (> 50 vs ≤ 50)	1.16	0.78–1.72	0.446
Drinking (present vs absent)	0.95	0.64–1.42	0.832
HBsAg (positive vs negative)	0.82	0.49–1.37	0.469
Tumor number (multiple vs single)	1.78	1.16–2.80	0.007
Tumor size, cm (> 5 vs ≤ 5)	2.61	1.73–3.37	< 0.001	1.75	1.23–2.67	0.003
Liver cirrhosis (present vs absent)	1.33	0.65–2.75	0.429
MVI (MVI vs non-MVI)	2.58	1.86–3.58	< 0.001	1.91	1.35–2.71	< 0.001
AFP, ng/ml (> 20 vs ≤ 20)	1.59	1.12–2.26	0.010
GLR (> 56 vs ≤ 56)	2.36	1.53–3.08	< 0.001	1.56	1.18–2.36	0.017
Overall survival
Sex (male vs female)	1.13	0.62–2.09	0.716
Age, y (> 50 vs ≤ 50)	1.08	0.73–1.61	0.671
Drinking (present vs absent)	0.83	0.56–1.24	0.371
HBsAg (positive vs negative)	0.72	0.43–1.21	0.224
Tumor number (multiple vs single)	1.83	1.20–2.66	0.004
Tumor size, cm (> 5 vs ≤ 5)	2.87	2.10–3.76	< 0.001	2.11	1.48–3.07	< 0.001
Liver cirrhosis (present vs absent)	1.13	0.55–2.33	0.732
MVI (MVI vs non-MVI)	2.83	2.05–3.61	< 0.001	2.00	1.41–2.84	< 0.001
AFP, ng/ml (> 20 vs ≤ 20)	1.64	1.15–2.33	0.006
GLR (> 56 vs ≤ 56)	2.47	1.80–3.40	< 0.001	1.63	1.28–2.31	0.006

HR hazard ratio, CI confidence interval, HBsAg hepatitis B surface antigen, MVI microvascular invasion, AFP alpha-fetoprotein, GLR GGT to lymphocyte ratio

ISSN: 1471-2407